K. C. Anderson

2.1k total citations
38 papers, 1.6k citations indexed

About

K. C. Anderson is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, K. C. Anderson has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in K. C. Anderson's work include Multiple Myeloma Research and Treatments (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). K. C. Anderson is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). K. C. Anderson collaborates with scholars based in United States, Canada and Netherlands. K. C. Anderson's co-authors include S F Schlossman, Lee M. Nadler, Michael Bates, J F Daley, Gemma Pidelaserra-Martí, Kimberly A. Kline, Bob G. Sanders, Karla A. Lawson, Jeffrey Atkinson and Marla Simmons-Menchaca and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

K. C. Anderson

38 papers receiving 1.6k citations

Peers

Countries citing papers authored by K. C. Anderson

Since Specialization

Citations

This map shows the geographic impact of K. C. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. C. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. C. Anderson more than expected).

Fields of papers citing papers by K. C. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. C. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. C. Anderson. The network helps show where K. C. Anderson may publish in the future.

Co-authorship network of co-authors of K. C. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of K. C. Anderson. A scholar is included among the top collaborators of K. C. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. C. Anderson. K. C. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs 2013 ·Leukemia ·Diana Cirstea, Teru Hideshima, Loredana Santo, Homare Eda, Yuji Mishima, Neeharika Nemani, Yiguo Hu, Naoya Mimura, Francesca Cottini, Güllü Görgün, Hiroto Ohguchi, Rikio Suzuki, Hannes Loferer, Nikhil C. Munshi, K. C. Anderson, Noopur Raje	47
2	Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. 2011 ·Journal of Clinical Oncology ·Brian G.M. Durie, (unknown), Jesús F. San Miguel, Robert Z. Orlowski, Sagar Lonial, Rubén Niesvizky, Zhinuan Yu, K. C. Anderson	2
3	Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. 2010 ·Journal of Clinical Oncology ·Andrzej Jakubowiak, (unknown), Jack W. Singer, David S. Siegel, Todd M. Zimmerman, Ann Mohrbacher, PG Richardson, Daniel Afar, Anil Singhal, K. C. Anderson	5
4	Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). 2010 ·Journal of Clinical Oncology ·Sundar Jagannath, (unknown), Roman Hájek, Meletios Α. Dimopoulos, (unknown), Sagar Lonial, Thorsten Graef, Lisa Lupinacci, (unknown), K. C. Anderson	1
5	Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. 2010 ·Journal of Clinical Oncology ·Phillip McCarthy, Kouros Owzar, K. C. Anderson, Craig C. Hofmeister, Hani Hassoun, David D. Hurd, Edward A. Stadtmauer, S. Giralt, Vera Hárs, Claudia Linker, (unknown)	55
6	Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's macroglobulinemia, and effect on miRNA expression. 2010 ·Journal of Clinical Oncology ·Douglas W. McMillin, Zachary R. Hunter, Jake Delmore, (unknown), Ann Birner, PG Richardson, K. C. Anderson, Steven P. Treon, Constantine S. Mitsiades	1
7	Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma. 2010 ·Journal of Clinical Oncology ·Noopur Raje, (unknown), Anuj Mahindra, Samantha Pozzi, PG Richardson, Jacob P. Laubach, Irene M. Ghobrial, R Schlossman, K. C. Anderson	2
8	ARQ 197, a small molecule inhibitor of c-met, prevents bone metastasis in a humanized mouse model of breast cancer 2007 ·Molecular Cancer Therapeutics ·K. C. Anderson, Chiang Li, Jodie E. Moreau, Thomas Chan, Michael Rosenblatt	7
9	α-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells 2006 ·APOPTOSIS ·Weiping Yu, Ming-Chieh Shun, K. C. Anderson, Hansong Chen, Bob G. Sanders, Kimberly A. Kline	26
10	Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials 2006 ·Leukemia ·Sundar Jagannath, Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Façon, Harousseau Jl, Janet M. Cowan, K. C. Anderson	183
11	Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients 2005 ·Clinical & Experimental Immunology ·Britta Maecker, Michael S. von Bergwelt‐Baildon, Karen S. Anderson, Robert H. Vonderheide, K. C. Anderson, Lee M. Nadler, Joachim L. Schultze	28
12	Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis 2004 ·Cancer Chemotherapy and Pharmacology ·Karla A. Lawson, K. C. Anderson, (unknown), Marla Simmons-Menchaca, Jeffrey Atkinson, Lu‐Zhe Sun, Abhik Bandyopadhyay, Vernon Knight, Brian E. Gilbert, Bob G. Sanders, Kimberly A. Kline	54
13	Comparison of Vitamin E Derivatives α-TEA and VES in Reduction of Mouse Mammary Tumor Burden and Metastasis 2004 ·Experimental Biology and Medicine ·Karla A. Lawson, K. C. Anderson, Marla Simmons-Menchaca, Jeffrey Atkinson, Lu‐Zhe Sun, Bob G. Sanders, Kimberly A. Kline	47
14	Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. 2003 ·PubMed ·Karla A. Lawson, K. C. Anderson, (unknown), Jeffrey Atkinson, Lu‐Zhe Sun, Vernon Knight, Brian E. Gilbert, Claudio J. Conti, Bob G. Sanders, Kimberly A. Kline	76
15	Immunotherapeutic strategies for the treatment of plasma cell malignancies. 2000 ·PubMed ·Steven P. Treon, Noopur Raje, K. C. Anderson	51
16	NCCN practice guidelines for multiple myeloma 1998 ·K. C. Anderson, Jack W. Singer, Sarah Bernstein, (unknown), Ruby F. Meredith, Joseph Michaeli, Stephen J. Noga, Keith Stockerl‐Goldstein, Ann Traynor, Donna M. Weber, Joachim Yahalom	3
17	Guidelines for blood utilization review 1994 ·Transfusion ·Linda C. Stehling, Naomi L.C. Luban, K. C. Anderson, Merlyn Sayers, Andrea Long, S Attar, Susan F. Leitman, S. A. C. Gould, Margot S. Kruskall, Lawrence T. Goodnough, D. Hines	95
18	Indications and guidelines for the use of hematopoietic growth factors 1993 ·Transfusion ·Lawrence T. Goodnough, K. C. Anderson, (unknown), T.A. Lane, Patricia Pisciotto, Merlyn Sayers, Leslie E. Silberstein	32
19	Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding 1993 ·Blood ·M. H. Lee, Evan Vosburgh, K. C. Anderson, J McDonagh	89
20	B protein of factor XIII: differentiation between free B and complexed B 1988 ·Blood ·Hiroshi Yorifuji, K. C. Anderson, (unknown), Livingston Van De Water, J McDonagh	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact